Logo image of IMCC

IM CANNABIS CORP (IMCC) Stock Fundamental Analysis

USA - NASDAQ:IMCC - CA44969Q4060 - Common Stock

1.94 USD
-0.03 (-1.52%)
Last: 9/19/2025, 8:19:16 PM
1.98 USD
+0.04 (+2.06%)
After Hours: 9/19/2025, 8:19:16 PM
Fundamental Rating

3

Overall IMCC gets a fundamental rating of 3 out of 10. We evaluated IMCC against 196 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IMCC have multiple concerns. While showing a medium growth rate, IMCC is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

IMCC had negative earnings in the past year.
IMCC had a positive operating cash flow in the past year.
In the past 5 years IMCC always reported negative net income.
In the past 5 years IMCC always reported negative operating cash flow.
IMCC Yearly Net Income VS EBIT VS OCF VS FCFIMCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a decent Return On Assets value of -10.43%, IMCC is doing good in the industry, outperforming 66.33% of the companies in the same industry.
IMCC has a Return On Equity (-88.04%) which is in line with its industry peers.
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROIC N/A
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
IMCC Yearly ROA, ROE, ROICIMCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

1.3 Margins

With a Gross Margin value of 18.58%, IMCC perfoms like the industry average, outperforming 51.02% of the companies in the same industry.
In the last couple of years the Gross Margin of IMCC has grown nicely.
IMCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
IMCC Yearly Profit, Operating, Gross MarginsIMCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMCC has more shares outstanding than it did 1 year ago.
IMCC has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IMCC is higher compared to a year ago.
IMCC Yearly Shares OutstandingIMCC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
IMCC Yearly Total Debt VS Total AssetsIMCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

IMCC has an Altman-Z score of -7.22. This is a bad value and indicates that IMCC is not financially healthy and even has some risk of bankruptcy.
IMCC has a Altman-Z score of -7.22. This is in the lower half of the industry: IMCC underperforms 65.31% of its industry peers.
The Debt to FCF ratio of IMCC is 4.09, which is a neutral value as it means it would take IMCC, 4.09 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.09, IMCC belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
IMCC has a Debt/Equity ratio of 2.52. This is a high value indicating a heavy dependency on external financing.
IMCC has a Debt to Equity ratio of 2.52. This is in the lower half of the industry: IMCC underperforms 77.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Altman-Z -7.22
ROIC/WACCN/A
WACC11.28%
IMCC Yearly LT Debt VS Equity VS FCFIMCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 0.72 indicates that IMCC may have some problems paying its short term obligations.
IMCC's Current ratio of 0.72 is on the low side compared to the rest of the industry. IMCC is outperformed by 88.27% of its industry peers.
IMCC has a Quick Ratio of 0.72. This is a bad value and indicates that IMCC is not financially healthy enough and could expect problems in meeting its short term obligations.
IMCC has a Quick ratio of 0.59. This is amonst the worse of the industry: IMCC underperforms 86.73% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.59
IMCC Yearly Current Assets VS Current LiabilitesIMCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

IMCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -78.84%.
Looking at the last year, IMCC shows a quite strong growth in Revenue. The Revenue has grown by 10.71% in the last year.
The Revenue has been growing by 16.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%

3.2 Future

IMCC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.54% yearly.
The Revenue is expected to grow by 26.24% on average over the next years. This is a very strong growth
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMCC Yearly Revenue VS EstimatesIMCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
IMCC Yearly EPS VS EstimatesIMCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

IMCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMCC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMCC Price Earnings VS Forward Price EarningsIMCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, IMCC is valued cheaper than 98.98% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.64
EV/EBITDA N/A
IMCC Per share dataIMCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as IMCC's earnings are expected to grow with 36.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

IMCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IM CANNABIS CORP

NASDAQ:IMCC (9/19/2025, 8:19:16 PM)

After market: 1.98 +0.04 (+2.06%)

1.94

-0.03 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners3.87%
Inst Owner Change89.29%
Ins Owners53.08%
Ins Owner ChangeN/A
Market Cap10.19M
Analysts82.86
Price TargetN/A
Short Float %0.26%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.69%
Min Revenue beat(2)-25.65%
Max Revenue beat(2)-9.73%
Revenue beat(4)1
Avg Revenue beat(4)-9.56%
Min Revenue beat(4)-25.65%
Max Revenue beat(4)9.9%
Revenue beat(8)3
Avg Revenue beat(8)-4.84%
Revenue beat(12)3
Avg Revenue beat(12)-9.88%
Revenue beat(16)5
Avg Revenue beat(16)-5.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF 3.64
P/OCF 3.5
P/B 2.64
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.45
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)0.53
FCFY27.51%
OCF(TTM)0.55
OCFY28.6%
SpS7.53
BVpS0.74
TBVpS-0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.43%
ROE -88.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.58%
FCFM 7.09%
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
F-Score7
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF 4.09
Debt/EBITDA N/A
Cap/Depr 7.98%
Cap/Sales 0.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.59
Altman-Z -7.22
F-Score7
WACC11.28%
ROIC/WACCN/A
Cap/Depr(3y)15.95%
Cap/Depr(5y)83.89%
Cap/Sales(3y)1.45%
Cap/Sales(5y)6.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y136.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.37%
OCF growth 3YN/A
OCF growth 5YN/A